Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 4.7%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)’s share price dropped 4.7% on Monday . The company traded as low as $13.09 and last traded at $13.09. Approximately 37,396 shares were traded during mid-day trading, a decline of 89% from the average daily volume of 354,533 shares. The stock had previously closed at $13.73.

Analyst Ratings Changes

YMAB has been the subject of a number of analyst reports. Canaccord Genuity Group upgraded shares of Y-mAbs Therapeutics to a “strong-buy” rating in a research note on Tuesday, August 13th. Truist Financial initiated coverage on shares of Y-mAbs Therapeutics in a research note on Friday, June 28th. They issued a “buy” rating and a $21.00 price objective for the company. Wedbush restated an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Morgan Stanley lowered their target price on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 price objective on shares of Y-mAbs Therapeutics in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $21.14.

Y-mAbs Therapeutics Stock Performance

The firm has a market capitalization of $572.23 million, a price-to-earnings ratio of -26.94 and a beta of 0.70. The business’s 50-day moving average is $12.86 and its two-hundred day moving average is $13.41.

Y-mAbs Therapeutics (NASDAQ:YMAB) last announced its earnings results on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08). The company had revenue of $22.80 million for the quarter, compared to analyst estimates of $23.09 million. Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. During the same quarter last year, the business posted ($0.14) earnings per share. Analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.57 EPS for the current year.

Insiders Place Their Bets

In other news, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at approximately $449,514. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, insider Thomas Gad sold 30,000 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $12.97, for a total value of $389,100.00. Following the completion of the transaction, the insider now directly owns 67,681 shares of the company’s stock, valued at $877,822.57. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Joris Wilms sold 5,000 shares of the firm’s stock in a transaction on Monday, August 26th. The shares were sold at an average price of $14.69, for a total transaction of $73,450.00. Following the completion of the transaction, the chief operating officer now directly owns 30,600 shares of the company’s stock, valued at $449,514. The disclosure for this sale can be found here. In the last three months, insiders have sold 100,000 shares of company stock worth $1,338,100. Company insiders own 21.50% of the company’s stock.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP boosted its position in Y-mAbs Therapeutics by 15.7% during the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after purchasing an additional 65,732 shares during the period. Millennium Management LLC raised its stake in Y-mAbs Therapeutics by 23.8% in the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after purchasing an additional 67,233 shares in the last quarter. Squarepoint Ops LLC raised its stake in Y-mAbs Therapeutics by 143.4% in the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock valued at $1,527,000 after purchasing an additional 74,452 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Y-mAbs Therapeutics by 8.0% during the second quarter. Bank of New York Mellon Corp now owns 120,954 shares of the company’s stock worth $1,461,000 after acquiring an additional 8,974 shares in the last quarter. Finally, Rice Hall James & Associates LLC raised its stake in Y-mAbs Therapeutics by 4.2% during the second quarter. Rice Hall James & Associates LLC now owns 89,735 shares of the company’s stock worth $1,084,000 after acquiring an additional 3,589 shares in the last quarter. 70.85% of the stock is owned by institutional investors.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.